|
Cardiovascular Diseases
|
0.390 |
GeneticVariation
|
group |
BEFREE |
To investigate the association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance (CR) in patients with cardiovascular disease in Beijing district.
|
29350207 |
2018 |
|
Cardiovascular Diseases
|
0.390 |
GeneticVariation
|
group |
BEFREE |
These alterations induced by Type II diabetes in the endogenous pathway (CYP450) of arachidonic acid metabolism may increase the risk for cardiovascular disease by disrupting the fine equilibrium between cardioprotective (CYP2J/CYP2C-generated) and cardiotoxic (CYP4A/CYP4F-generated) metabolites of arachidonic acid.
|
29023376 |
2017 |
|
Cardiovascular Diseases
|
0.390 |
GeneticVariation
|
group |
BEFREE |
Approximately, 59.0% of Korean patients with cardiovascular disease receiving clopidogrel had CYP2C19 loss-of-function genotypes classified as IM or PM, and the frequency was similar to the data from Asian people.
|
26522758 |
2016 |
|
Cardiovascular Diseases
|
0.390 |
GeneticVariation
|
group |
BEFREE |
CYP2C19 genetic polymorphisms influence clopidogrel response and clinical outcomes of cardiovascular disease.
|
25489921 |
2015 |
|
Cardiovascular Diseases
|
0.390 |
GeneticVariation
|
group |
BEFREE |
The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.
|
24782221 |
2014 |
|
Cardiovascular Diseases
|
0.390 |
Biomarker
|
group |
BEFREE |
In this medium-size group of patients with stable CHD homozygous carriers of the loss-of-function allele CYP2C19*2 were at increased risk for subsequent CVD events during 8 year follow-up independent of other risk factors.
|
23981380 |
2013 |
|
Cardiovascular Diseases
|
0.390 |
Biomarker
|
group |
BEFREE |
Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: a systematic review and meta-analysis.
|
22757746 |
2013 |
|
Cardiovascular Diseases
|
0.390 |
Biomarker
|
group |
BEFREE |
Recent findings suggest that CYP2C19 gene might be considered as a novel candidate gene for treatment of cardiovascular disease.
|
23074110 |
2012 |
|
Cardiovascular Diseases
|
0.390 |
GeneticVariation
|
group |
BEFREE |
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.
|
22088980 |
2011 |
|
Cardiovascular Diseases
|
0.390 |
Biomarker
|
group |
CTD_human |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
|
20978260 |
2010 |
|
Depressive disorder
|
0.380 |
Biomarker
|
disease |
BEFREE |
182 subjects diagnosed with depression and treated with these drugs were clinically and therapeutically characterized and submitted to the quantification of drug/metabolite plasma concentrations and genotyping of ABCB1, CYP2C9, CYP2C19, and CYP2D6 genes.
|
31120287 |
2020 |
|
Depressive disorder
|
0.380 |
Biomarker
|
disease |
BEFREE |
Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders.
|
30837874 |
2019 |
|
Depressive disorder
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
Thus, we studied the effects of polymorphisms of the CYP2C19 gene on raw plasma drug concentrations in Japanese patients with depression.
|
29570504 |
2018 |
|
Depressive disorder
|
0.380 |
Biomarker
|
disease |
BEFREE |
In humans, we found that the absence of CYP2C19 was associated with a bilateral hippocampal volume increase in two independent healthy cohorts (N=386 and 1032) and a lower prevalence of major depressive disorder and depression severity in African-Americans (N=3848).
|
27895323 |
2017 |
|
Depressive disorder
|
0.380 |
Biomarker
|
disease |
BEFREE |
Herein, we present the case of a 29-year-old male with diagnoses of depression and obsessive compulsive disorder who had trialed and failed a dozen psychiatric medications, many of which are subject to metabolism by CYP2D6 and/or CYP2C19, and had most recently been taking clomipramine for approximately 2.5 years.
|
28470111 |
2017 |
|
Depressive disorder
|
0.380 |
Biomarker
|
disease |
PSYGENET |
We report the effect of CYP2C19 and CYP2D6 genotypes on steady state morning concentrations of escitalopram and N-desmethylescitalopram and the ratio of this metabolite to the parent drug in 196 adult patients with depression in GENDEP, a clinical pharmacogenomic trial.
|
21926427 |
2012 |
|
Depressive disorder
|
0.380 |
Biomarker
|
disease |
BEFREE |
We report the effect of CYP2C19 and CYP2D6 genotypes on steady state morning concentrations of escitalopram and N-desmethylescitalopram and the ratio of this metabolite to the parent drug in 196 adult patients with depression in GENDEP, a clinical pharmacogenomic trial.
|
21926427 |
2012 |
|
Depressive disorder
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
The Sequenced Treatment Alternatives to Relieve Depression sample was used to examine the relationship between variations in the CYP2C19 and CYP2D6 genes and remission of depressive symptoms and tolerance to treatment with citalopram.
|
21192344 |
2011 |
|
Depressive disorder
|
0.380 |
Biomarker
|
disease |
PSYGENET |
The Sequenced Treatment Alternatives to Relieve Depression sample was used to examine the relationship between variations in the CYP2C19 and CYP2D6 genes and remission of depressive symptoms and tolerance to treatment with citalopram.
|
21192344 |
2011 |
|
Depressive disorder
|
0.380 |
Biomarker
|
disease |
PSYGENET |
We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.
|
16812949 |
2006 |
|
Depressive disorder
|
0.380 |
Biomarker
|
disease |
BEFREE |
Genetic tests suitable for the routine laboratory are now available for some important metabolizing enzymes (e.g., CYP2D6, CYP2C19) identifying those individuals who are slow or fast metabolizers of certain drugs, many of which are widely used in the treatment of depression (e.g., tricyclic antidepressants).
|
11412815 |
2001 |
|
Depressive disorder
|
0.380 |
Biomarker
|
disease |
PSYGENET |
Genetic tests suitable for the routine laboratory are now available for some important metabolizing enzymes (e.g., CYP2D6, CYP2C19) identifying those individuals who are slow or fast metabolizers of certain drugs, many of which are widely used in the treatment of depression (e.g., tricyclic antidepressants).
|
11412815 |
2001 |
|
Mental Depression
|
0.370 |
Biomarker
|
disease |
BEFREE |
182 subjects diagnosed with depression and treated with these drugs were clinically and therapeutically characterized and submitted to the quantification of drug/metabolite plasma concentrations and genotyping of ABCB1, CYP2C9, CYP2C19, and CYP2D6 genes.
|
31120287 |
2020 |
|
Mental Depression
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
Thus, we studied the effects of polymorphisms of the CYP2C19 gene on raw plasma drug concentrations in Japanese patients with depression.
|
29570504 |
2018 |
|
Mental Depression
|
0.370 |
Biomarker
|
disease |
BEFREE |
In humans, we found that the absence of CYP2C19 was associated with a bilateral hippocampal volume increase in two independent healthy cohorts (N=386 and 1032) and a lower prevalence of major depressive disorder and depression severity in African-Americans (N=3848).
|
27895323 |
2017 |